ZSAN Zosano Pharma Corporation

1.31
-0.03  -2%
Previous Close 1.34
Open 1.34
Price To Book 2.3
Market Cap 23,860,475
Shares 18,230,803
Volume 188,202
Short Ratio
Av. Daily Volume 423,591
Stock charts supplied by TradingView

NewsSee all news

  1. Zosano Announces FDA Submission of New Drug Application for Qtrypta

    FREMONT, Calif., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the submission of a 505(b)(2) New Drug Application ("NDA") for

  2. Zosano Announces Pricing of Registered Direct Offering

    FREMONT, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with

  3. Zosano Pharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    FREMONT, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2019,

  4. Zosano Pharma Announces Completion of Pre-NDA Meetings with FDA for Qtrypta™

    FREMONT, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has received minutes from pre- New Drug Application

  5. Zosano Pharma to Host Conference Call on Third Quarter 2019 Financial Results and Provide Operational Update

    FREMONT, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Thursday,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial data due released February 13, 2017 - primary endpoints met.
M207
Migraine
Phase 2 data released September 2015. Considering Phase 3 initiation in 2016
ZP-Glucagon
Severe hypoglycemia
NDA filing announced December 23, 2019.
Qtrypta (M207)
Migraine
Phase 2/3 trial initiation announced October 24, 2019.
C213
Cluster headache

Latest News

  1. Zosano Announces FDA Submission of New Drug Application for Qtrypta

    FREMONT, Calif., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the submission of a 505(b)(2) New Drug Application ("NDA") for

  2. Zosano Announces Pricing of Registered Direct Offering

    FREMONT, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with

  3. Zosano Pharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    FREMONT, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2019,

  4. Zosano Pharma Announces Completion of Pre-NDA Meetings with FDA for Qtrypta™

    FREMONT, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has received minutes from pre- New Drug Application

  5. Zosano Pharma to Host Conference Call on Third Quarter 2019 Financial Results and Provide Operational Update

    FREMONT, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Thursday,

  6. Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    FREMONT, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Board of Directors granted a stock option to purchase

  7. Zosano Pharma Announces CEO Transition

    FREMONT, Calif., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that Steven Lo, veteran biotechnology and pharmaceutical

  8. Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    FREMONT, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Board of Directors granted a stock option to purchase

  9. Zosano Pharma to Present at the Cantor Global Healthcare Conference

    FREMONT, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John

  10. Zosano Pharma Announces the Appointment of Dushyant Pathak, Ph.D., as Senior Vice President of Business Development

    FREMONT, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Dushyant Pathak, Ph.D., as senior vice

  11. Zosano Pharma Announces the Presentation of Multiple Positive Datasets from the Qtrypta™ Long-Term Safety Study at the Congress of the International Headache Society

    - Repeated Dosing of Qtrypta Over the Course of One Year Reaffirms Qtrypta is Effective and Well-Tolerated as an Acute Treatment for Migraine - - Efficacy and Safety Profile Consistent in Sub Analyses of Patients Taking

  12. Zosano Pharma to Present at the H.C. Wainwright Annual Global Investment Conference

    FREMONT, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John

  13. Zosano Pharma Announces Upcoming Oral and Poster Presentations at the Congress of the International Headache Society

    Oral presentation of the safety and efficacy of QtryptaTM in a long-term safety study for the acute treatment of migraine.Poster on the results of patients' freedom from pain and most bothersome symptom when taking